Novel therapeutic strategies by regulatory T cells in allergy

E. Elkord*

*Corresponding author for this work

Research output: Chapter in Book or Report/Conference proceedingChapterpeer-review

6 Citations (Scopus)

Abstract

Natural CD4+CD25+FoxP3+ regulatory T cells (Treg) actively suppress physiological and pathological responses, therefore playing a critical role in controlling peripheral tolerance to self antigens and maintaining immune homeostasis. In normal individuals, natural Treg and interleukin- 10-secreting Treg are able to suppress Th2 responses to allergens, whereas lower levels of Treg or defect in their functionality have been described as potential mechanisms for inducing allergic diseases. In animal models, adoptive transfer of CD4+CD25+Treg has been shown as a promising strategy for preventing or treating allergic disorders. Recent studies show that induction of Treg activity is associated with suppression of allergic responses in allergic patients treated with specific immunotherapy. Herein, I review the potential of Treg as exciting targets for developing new immunotherapeutic strategies for treating allergic diseases.

Original languageEnglish
Title of host publicationT Cell Regulation in Allergy, Asthma and Atopic Skin Diseases
EditorsKurt Blaser
Pages150-157
Number of pages8
DOIs
Publication statusPublished - 2008
Externally publishedYes

Publication series

NameChemical Immunology and Allergy
Volume94
ISSN (Print)1660-2242

Fingerprint

Dive into the research topics of 'Novel therapeutic strategies by regulatory T cells in allergy'. Together they form a unique fingerprint.

Cite this

Elkord, E. (2008). Novel therapeutic strategies by regulatory T cells in allergy. In K. Blaser (Ed.), T Cell Regulation in Allergy, Asthma and Atopic Skin Diseases (pp. 150-157). (Chemical Immunology and Allergy; Vol. 94). https://doi.org/10.1159/000154999